Publication: Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy
Open/View Files
Date
2015
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A.
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Jiang, Yinghua, Xiang Fan, Zhanyang Yu, Zhengbu Liao, Xiao-Shu Wang, Klaus van Leyen, Xiaochuan Sun, Eng H. Lo, and Xiaoying Wang. 2015. “Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy.” Frontiers in Cellular Neuroscience 9 (1): 397. doi:10.3389/fncel.2015.00397. http://dx.doi.org/10.3389/fncel.2015.00397.
Research Data
Abstract
Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of low-dose tPA plus recombinant annexin A2 (rA2, a tPA, and plasminogen co-receptor), which might enhance tPA thrombolytic efficacy, while reducing its associated complications related to intracerebral hemorrhagic transformation. Results of our experimental studies using a focal embolic stroke model in rats support the feasibility of the combination approach and suggest the potential for successful clinical translation.
Description
Other Available Sources
Keywords
Mini Review, cerebral ischemia, tissue-type plasminogen activator, annexin A2, thrombolysis, combination therapy, focal embolic stroke model, rats
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service